Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells

Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental cell research 1996-10, Vol.228 (1), p.76-83
Hauptverfasser: Warburton, Michael J., Dundas, Sinclair R., Gusterson, Barry A., O'Hare, Michael J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 83
container_issue 1
container_start_page 76
container_title Experimental cell research
container_volume 228
creator Warburton, Michael J.
Dundas, Sinclair R.
Gusterson, Barry A.
O'Hare, Michael J.
description Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity.
doi_str_mv 10.1006/excr.1996.0301
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1006_excr_1996_0301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482796903018</els_id><sourcerecordid>8892973</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-ae8297ed2469673b88f0fd42d6ef76d50fe9cffb00eb2cf9ddce300245e67c993</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EKqWwZYfkH0iZOGliL1HFS2pFVbXr4NjjYkjiyk4r-vcktGLHahZ3ztXVIeQ2hnEMkN3jt_LjWIhsDAnEZ2QYg4CIpYydkyFAnEYpZ_kluQrhEwA4j7MBGXAumMiTIXlf4mZXyda6hjpD19592UYGjFaHLdJFJUNtG7fBhj6o1u5l6zxdeKd36hcpD3QpWzqXdS39gc4PDre2_cDKyopOsarCNbkwsgp4c7ojsn56XE1fotnb8-v0YRapJBFtJJF3g1CzNBNZnpScGzA6ZTpDk2d6AgaFMqYEwJIpI7RWmACwdIJZroRIRmR87FXeheDRFFtv-1FFDEVvquhNFb2pojfVAXdHYLsra9R_7yc1Xc6POXar9xZ9EZTFRqG2HlVbaGf_q_4BzK56Mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Warburton, Michael J. ; Dundas, Sinclair R. ; Gusterson, Barry A. ; O'Hare, Michael J.</creator><creatorcontrib>Warburton, Michael J. ; Dundas, Sinclair R. ; Gusterson, Barry A. ; O'Hare, Michael J.</creatorcontrib><description>Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1006/excr.1996.0301</identifier><identifier>PMID: 8892973</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Basement Membrane - drug effects ; Basement Membrane - metabolism ; Cell Line ; Cytokines - pharmacology ; Enzyme Induction - drug effects ; Epithelial Cells ; Epithelium - drug effects ; Epithelium - metabolism ; Female ; Fibroblast Growth Factor 2 - pharmacology ; Growth Substances - pharmacology ; Hormones - pharmacology ; Hydrocortisone - pharmacology ; Interleukin-1 - pharmacology ; Mammary Glands, Animal - cytology ; Mammary Glands, Animal - drug effects ; Mammary Glands, Animal - metabolism ; Plasminogen Activators - biosynthesis ; Rats ; Tetradecanoylphorbol Acetate - pharmacology ; Transforming Growth Factor beta - pharmacology ; Urokinase-Type Plasminogen Activator - biosynthesis</subject><ispartof>Experimental cell research, 1996-10, Vol.228 (1), p.76-83</ispartof><rights>1996 Academic Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-ae8297ed2469673b88f0fd42d6ef76d50fe9cffb00eb2cf9ddce300245e67c993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1006/excr.1996.0301$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8892973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Warburton, Michael J.</creatorcontrib><creatorcontrib>Dundas, Sinclair R.</creatorcontrib><creatorcontrib>Gusterson, Barry A.</creatorcontrib><creatorcontrib>O'Hare, Michael J.</creatorcontrib><title>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity.</description><subject>Animals</subject><subject>Basement Membrane - drug effects</subject><subject>Basement Membrane - metabolism</subject><subject>Cell Line</subject><subject>Cytokines - pharmacology</subject><subject>Enzyme Induction - drug effects</subject><subject>Epithelial Cells</subject><subject>Epithelium - drug effects</subject><subject>Epithelium - metabolism</subject><subject>Female</subject><subject>Fibroblast Growth Factor 2 - pharmacology</subject><subject>Growth Substances - pharmacology</subject><subject>Hormones - pharmacology</subject><subject>Hydrocortisone - pharmacology</subject><subject>Interleukin-1 - pharmacology</subject><subject>Mammary Glands, Animal - cytology</subject><subject>Mammary Glands, Animal - drug effects</subject><subject>Mammary Glands, Animal - metabolism</subject><subject>Plasminogen Activators - biosynthesis</subject><subject>Rats</subject><subject>Tetradecanoylphorbol Acetate - pharmacology</subject><subject>Transforming Growth Factor beta - pharmacology</subject><subject>Urokinase-Type Plasminogen Activator - biosynthesis</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EKqWwZYfkH0iZOGliL1HFS2pFVbXr4NjjYkjiyk4r-vcktGLHahZ3ztXVIeQ2hnEMkN3jt_LjWIhsDAnEZ2QYg4CIpYydkyFAnEYpZ_kluQrhEwA4j7MBGXAumMiTIXlf4mZXyda6hjpD19592UYGjFaHLdJFJUNtG7fBhj6o1u5l6zxdeKd36hcpD3QpWzqXdS39gc4PDre2_cDKyopOsarCNbkwsgp4c7ojsn56XE1fotnb8-v0YRapJBFtJJF3g1CzNBNZnpScGzA6ZTpDk2d6AgaFMqYEwJIpI7RWmACwdIJZroRIRmR87FXeheDRFFtv-1FFDEVvquhNFb2pojfVAXdHYLsra9R_7yc1Xc6POXar9xZ9EZTFRqG2HlVbaGf_q_4BzK56Mw</recordid><startdate>19961010</startdate><enddate>19961010</enddate><creator>Warburton, Michael J.</creator><creator>Dundas, Sinclair R.</creator><creator>Gusterson, Barry A.</creator><creator>O'Hare, Michael J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19961010</creationdate><title>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</title><author>Warburton, Michael J. ; Dundas, Sinclair R. ; Gusterson, Barry A. ; O'Hare, Michael J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-ae8297ed2469673b88f0fd42d6ef76d50fe9cffb00eb2cf9ddce300245e67c993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Basement Membrane - drug effects</topic><topic>Basement Membrane - metabolism</topic><topic>Cell Line</topic><topic>Cytokines - pharmacology</topic><topic>Enzyme Induction - drug effects</topic><topic>Epithelial Cells</topic><topic>Epithelium - drug effects</topic><topic>Epithelium - metabolism</topic><topic>Female</topic><topic>Fibroblast Growth Factor 2 - pharmacology</topic><topic>Growth Substances - pharmacology</topic><topic>Hormones - pharmacology</topic><topic>Hydrocortisone - pharmacology</topic><topic>Interleukin-1 - pharmacology</topic><topic>Mammary Glands, Animal - cytology</topic><topic>Mammary Glands, Animal - drug effects</topic><topic>Mammary Glands, Animal - metabolism</topic><topic>Plasminogen Activators - biosynthesis</topic><topic>Rats</topic><topic>Tetradecanoylphorbol Acetate - pharmacology</topic><topic>Transforming Growth Factor beta - pharmacology</topic><topic>Urokinase-Type Plasminogen Activator - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Warburton, Michael J.</creatorcontrib><creatorcontrib>Dundas, Sinclair R.</creatorcontrib><creatorcontrib>Gusterson, Barry A.</creatorcontrib><creatorcontrib>O'Hare, Michael J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Warburton, Michael J.</au><au>Dundas, Sinclair R.</au><au>Gusterson, Barry A.</au><au>O'Hare, Michael J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>1996-10-10</date><risdate>1996</risdate><volume>228</volume><issue>1</issue><spage>76</spage><epage>83</epage><pages>76-83</pages><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>Addition of basic fibroblast growth factor (bFGF) to a rat mammary gland myoepithelial cell line (25.5−G4.2.3) resulted in a six- to eightfold increase in cellular and secreted urokinase-type plasminogen activator (uPA) activity after a lag phase of 5–8 h. bFGF had no effect on the uPA activity of mammary epithelial cells. bFGF was active on myoepithelial cells over a narrow concentration range (0.5–2 ng/ml). The bFGF-induced increase in uPA activity was inhibited in a dose-dependent manner by hydrocortisone and transforming growth factor-β1 (TGF-β1). Hydrocortisone also inhibited the basal secretion of uPA, as did interleukin-1β and phorbol myristate acetate, both of which increase uPA levels in other cell systems. The effects of bFGF could also be inhibited by factors which bind bFGF, e.g., heparin and methylamine a2-macroglobulin. TGF-β1, but not bFGF, induced the synthesis of plasminogen activator inhibitor-1 in the myoepithelial cell line. Mammary gland myoepithelial cells contribute to the synthesis of and are located next to the basement membrane. Myoepithelial-derived uPA is probably associated with basement membrane turnover. The mammary gland basement membrane undergoes many cycles of remodeling and multiple mechanisms may be required to regulate uPA activity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>8892973</pmid><doi>10.1006/excr.1996.0301</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-4827
ispartof Experimental cell research, 1996-10, Vol.228 (1), p.76-83
issn 0014-4827
1090-2422
language eng
recordid cdi_crossref_primary_10_1006_excr_1996_0301
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Basement Membrane - drug effects
Basement Membrane - metabolism
Cell Line
Cytokines - pharmacology
Enzyme Induction - drug effects
Epithelial Cells
Epithelium - drug effects
Epithelium - metabolism
Female
Fibroblast Growth Factor 2 - pharmacology
Growth Substances - pharmacology
Hormones - pharmacology
Hydrocortisone - pharmacology
Interleukin-1 - pharmacology
Mammary Glands, Animal - cytology
Mammary Glands, Animal - drug effects
Mammary Glands, Animal - metabolism
Plasminogen Activators - biosynthesis
Rats
Tetradecanoylphorbol Acetate - pharmacology
Transforming Growth Factor beta - pharmacology
Urokinase-Type Plasminogen Activator - biosynthesis
title Regulation of Urokinase-Type Plasminogen Activator Production by Rat Mammary Myoepithelial Cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T00%3A55%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulation%20of%20Urokinase-Type%20Plasminogen%20Activator%20Production%20by%20Rat%20Mammary%20Myoepithelial%20Cells&rft.jtitle=Experimental%20cell%20research&rft.au=Warburton,%20Michael%20J.&rft.date=1996-10-10&rft.volume=228&rft.issue=1&rft.spage=76&rft.epage=83&rft.pages=76-83&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1006/excr.1996.0301&rft_dat=%3Cpubmed_cross%3E8892973%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8892973&rft_els_id=S0014482796903018&rfr_iscdi=true